Nicholls, Stephen J.

Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials

Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 52

Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: a VOYAGER analysis

Palmer, M. K., Barter, P. J., Lundman, P., Nicholls, S. J., Toth, P. P., & Karlson, B. W. (2019) · Clinical Biochemistry

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 49

Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement From the Cardiac Society of Australia and New Zealand (CSANZ)

Nicholls, S. J., Nelson, M., Astley, C., Briffa, T., Brown, A., Clark, R., Colquhoun, D., Gallagher, R., Hare, D. L., Inglis, S., et al. (2020) · Heart, Lung and Circulation

Cardiac Health and Mental HealthCOVID-19 and healthcare impacts

Cited by 43

Examining adherence to activity monitoring devices to improve physical activity in adults with cardiovascular disease: A systematic review

Marin, T. S., Kourbelis, C., Foote, J., Newman, P., Brown, A., Daniel, M., Coffee, N. T., Nicholls, S. J., Ganesan, A., Versace, V. L., et al. (2019) · European Journal of Preventive Cardiology

Physical Activity and HealthMobile Health and mHealth Applications

Cited by 33

Abstract 17120: ARO-ANG3, an investigational RNAi therapeutic, silences the expression of ANGPTL3 and decreases atherogenic lipoproteins in patients with mixed dyslipidemia: ARCHES-2 study results

Watts, G. F., Gaudet, D., ALTAMIRANO, D., Hegele, R., Ballantyne, C. M., Nicholls, S., Chang, T., Alagarsamy, S., Fu, R., San Martin, J., et al. (2023) · Circulation

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 9

Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial

Nicholls, S. J., Ray, K. K., Lincoff, A. M., Sarnes, E., Gillard, K. K., Bloedon, L., Migliaccio-Walle, K., Elsea, D., & Nissen, S. E. (2026) · American Journal of Cardiovascular Drugs

Lipoproteins and Cardiovascular HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 4

Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis

Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 0